Literature DB >> 24548143

Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.

Sarah Broeckx, Bizunesh M Borena, Marieke Zimmerman, Tom Mariën, Bert Seys, Marc Suls, Luc Duchateau, Jan H Spaas1.   

Abstract

It has been reported that mesenchymal stem cells (MSCs) have homing capacities and immunomodulating effects after an intravenous injection. However, transplanting MSCs in murine tail veins can result in pulmonary reactions and even death of the animals. Unfortunately, only a few intravenous MSC transplantations have been reported in large animal species and these were performed in a limited number of individuals. To assess the safety of MSC transplantations, a large study on 291 recipient horses is reported here. MSCs were isolated from the peripheral blood (PB) of a 4-year-old and 6-year-old donor horse after having tested their PB for a wide range of transmittable diseases. The MSC samples from both donor horses were characterized and resuspended in 1 ml of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Dimethyl Sulfoxide (DMSO). After hand-thawing in the field, 291 horses with ages ranging from 3-months to 33-years were directly injected into their jugular vein. 281 horses (97%) received a single injection of a physiological dose of 0.2 x10(6) MSCs, 5 horses (1.7%) were re-injected after approximately 6 weeks (using the same dose and donor cells) and a single superphysiological dose of 10(6) MSCs was administered to 5 horses as well. In total, 176 recipients were injected with MSCs from the 4-year-old donor and 115 recipients received MSCs from the 6-year-old donor. From all the injected horses (n=291) no acute clinical adverse effects were noticed. Apart from one horse that died of colic 7 months after the treatment, no deaths were registered and all the horses were monitored for 1 year after the injection. In conclusion, no adverse effects were noticed in 291 recipients after an intravenous injection of allogenic PBderived MSCs. Nevertheless, further research is warranted in order to verify the immunogenic properties of these cells after allogenic transplantation into various (patho)physiological sites.

Entities:  

Mesh:

Year:  2014        PMID: 24548143     DOI: 10.2174/1574888x09666140220003847

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  12 in total

1.  Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology.

Authors:  Chiara Gomiero; Giulia Bertolutti; Tiziana Martinello; Nathalie Van Bruaene; Sarah Y Broeckx; Marco Patruno; Jan H Spaas
Journal:  Vet Res Commun       Date:  2016-01-13       Impact factor: 2.459

2.  Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.

Authors:  Amir Kol; Joshua A Wood; Danielle D Carrade Holt; Jessica A Gillette; Laurie K Bohannon-Worsley; Sarah M Puchalski; Naomi J Walker; Kaitlin C Clark; Johanna L Watson; Dori L Borjesson
Journal:  Stem Cell Res Ther       Date:  2015-04-15       Impact factor: 6.832

3.  Allogeneic transplantation of mobilized dental pulp stem cells with the mismatched dog leukocyte antigen type is safe and efficacious for total pulp regeneration.

Authors:  Koichiro Iohara; Shinji Utsunomiya; Sakae Kohara; Misako Nakashima
Journal:  Stem Cell Res Ther       Date:  2018-04-27       Impact factor: 6.832

Review 4.  The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.

Authors:  Elizabeth S MacDonald; Jennifer G Barrett
Journal:  Front Vet Sci       Date:  2020-01-21

5.  Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses.

Authors:  Suzanne J K Mund; Daniel J MacPhee; John Campbell; Ali Honaramooz; Bruce Wobeser; Spencer M Barber
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

6.  Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.

Authors:  Aimée C Colbath; Steven W Dow; Leone S Hopkins; Jennifer N Phillips; C Wayne McIlwraith; Laurie R Goodrich
Journal:  Equine Vet J       Date:  2020-02-14       Impact factor: 2.888

7.  Tenogenically Induced Allogeneic Mesenchymal Stem Cells for the Treatment of Proximal Suspensory Ligament Desmitis in a Horse.

Authors:  Aurélie Vandenberghe; Sarah Y Broeckx; Charlotte Beerts; Bert Seys; Marieke Zimmerman; Ineke Verweire; Marc Suls; Jan H Spaas
Journal:  Front Vet Sci       Date:  2015-10-22

8.  Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.

Authors:  Lynn B Williams; Carmon Co; Judith B Koenig; Crystal Tse; Emily Lindsay; Thomas G Koch
Journal:  Front Vet Sci       Date:  2016-07-22

9.  Tenogenically Induced Allogeneic Peripheral Blood Mesenchymal Stem Cells in Allogeneic Platelet-Rich Plasma: 2-Year Follow-up after Tendon or Ligament Treatment in Horses.

Authors:  Charlotte Beerts; Marc Suls; Sarah Y Broeckx; Bert Seys; Aurélie Vandenberghe; Jeroen Declercq; Luc Duchateau; Martin A Vidal; Jan H Spaas
Journal:  Front Vet Sci       Date:  2017-09-26

10.  Homing and Engraftment of Intravenously Administered Equine Cord Blood-Derived Multipotent Mesenchymal Stromal Cells to Surgically Created Cutaneous Wound in Horses: A Pilot Project.

Authors:  Suzanne J K Mund; Eiko Kawamura; Awang Hazmi Awang-Junaidi; John Campbell; Bruce Wobeser; Daniel J MacPhee; Ali Honaramooz; Spencer Barber
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.